维普中文期刊产品整合服务
43篇 您的检索式:作者名="Mileshkin L"
    题名 作者 年代 出处 被引量
1Massively - parallel sequencing assists the diagnosis and guided treatment of cancers of unknown pri- mary显示文摘Tothill R W Li J Mileshkin L 2013The Journal of pathology2013,231,4:1
2An analysis of clinical trials assessing the efficacy and safety of singleagent thalidomide in patients with relapsed or refractory multiple myeloma显示文摘Prince HM Schenkel B Mileshkin L 2007Leuk Lymphoma2007,48,:1
3Hemoglobin level in cervical cancer: a surrogate for an infiltrative phenotype 显示文摘Barkati M Fortin I Mileshkin L 2013IntJ Gynecol Cancer2013,23,4:1
4A multieenter phase H trial of thalidomide and eelecoxib for patients with relapsed and refractory multiple myeloma显示文摘Prince HM Mileshkin L Roberts A 2005Clin Cancer Res2005,11,15:1
5Rational use of trastuzumab in me- tastatic and locally advanced breast cancer: implications of recent research显示文摘Goel S Chirgwin J Francis P Stuart-Harris R Dewar J Mileshkin L 2011Breast2011,20,:1
6A muhi- center phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma 显示文摘PRINCE HM MILESHKIN L ROBERTS A 2005Clin Cancer Res2005,11,15:1
7Multicentex phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age显示文摘Mileshkin L Biagi JJ mitchell P 2003Blood2003,102,:1
8An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma显示文摘PRINCE H M SCHENKEL B MILESHKIN L 2007Leuk Lymphoma2007,48,:1
9Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre 显示文摘Au-Yeung G Mileshkin L Bernshaw DM 2013J Med Imaging Radiat Oncol2013,57,1:1
10An analysis of clinical trials as- sessing the efficacy and safety of single-agent thalidmnide in patients with relapsed or refractory multiple myeloma显示文摘Prince HM Schenkel B Mileshkin L 2007Leuk Lymphoma2007,48,1:1
11Serum MUCI as a marker of disease status in multiple mycloma patients receiving thalidomide 显示文摘Mileshkin L Prince HM Seymour JF 2003Br J Haematol2003,123,4:1
12Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide显示文摘Mileshkin L Prince HM Seymour JF 2003BrJ Haematol2003,123,4:1
13An analsis of clinical trials assessing the efficacy and safety of single - agent thalidomide in patients with relapsed or refractory multiple myelpma显示文摘Prince HM Schenkel B Mileshkin L 2007Leuk Lymphoma2007,48,1:1
14Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation显示文摘Biagi JJ Mileshkin L Grigg AP 2001Bone Marrow Transplant2001,28,12:1
15A multicenter phase Ⅱ trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma显示文摘Prince HM Mileshkin L Roberts A 2005Clin Cancer Res2005,11,15:1
16Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring显示文摘Mileshkin L Stark R Day B 2006J Clin Oncol2006,24,:1
17An analysis of clinical trials assessing the efficacy and safety of singe-agent thalidomide in patients with relapsed or refractory multiple myeloma显示文摘Prince H M Schenkel B Mileshkin L 2007Leuk Lymphoma2007,48,1:1
18A multicenter phase Ⅱ trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma显示文摘Prince HM Mileshkin L Roberts A 2005Clin Cancer Res2005,11,15:1
19Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase Ⅱ Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography Imaging显示文摘Hughes B Mileshkin L Townley P 2014Oncologist2014,19,2:1
20An analysis of clinical trialsassessing the efficacy and safety of single-agent thalidomide in pa-tients with relapsed or refractory multiple myeloma显示文摘Prince HM Schenkel B Mileshkin L 2007Leuk Lym-phoma2007,48,1:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费